NASDAQ:ZGNX - Zogenix Stock Price, News, & Analysis

$47.93
+0.37 (+0.78 %)
(As of 07/18/2019 01:24 PM ET)
Today's Range
$47.44
Now: $47.93
$48.14
50-Day Range
$37.27
MA: $42.84
$48.68
52-Week Range
$33.43
Now: $47.93
$61.00
Volume6,241 shs
Average Volume683,293 shs
Market Capitalization$2.03 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.04
Zogenix, Inc, a pharmaceutical company, develops and commercializes therapies for the treatment of transformative central nervous system disorders in the United States. Its lead product candidate is the Fintepla/ZX008, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome. The company was formerly known as SJ2 Therapeutics, Inc and changed its name to Zogenix, Inc in August 2006. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNASDAQ:ZGNX
CUSIP98978L10
Phone510-550-8300

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$9.82 million
Book Value$12.46 per share

Profitability

Net Income$-123,910,000.00

Miscellaneous

Employees90
Market Cap$2.03 billion
Next Earnings Date8/5/2019 (Estimated)
OptionableOptionable

Receive ZGNX News and Ratings via Email

Sign-up to receive the latest news and ratings for ZGNX and its competitors with MarketBeat's FREE daily newsletter.

Zogenix (NASDAQ:ZGNX) Frequently Asked Questions

What is Zogenix's stock symbol?

Zogenix trades on the NASDAQ under the ticker symbol "ZGNX."

How were Zogenix's earnings last quarter?

Zogenix, Inc. (NASDAQ:ZGNX) issued its quarterly earnings results on Wednesday, May, 8th. The company reported ($0.83) EPS for the quarter, beating analysts' consensus estimates of ($0.85) by $0.02. View Zogenix's Earnings History.

When is Zogenix's next earnings date?

Zogenix is scheduled to release their next quarterly earnings announcement on Monday, August 5th 2019. View Earnings Estimates for Zogenix.

What price target have analysts set for ZGNX?

12 equities research analysts have issued twelve-month price targets for Zogenix's stock. Their forecasts range from $48.00 to $116.00. On average, they anticipate Zogenix's share price to reach $64.4545 in the next twelve months. This suggests a possible upside of 34.5% from the stock's current price. View Analyst Price Targets for Zogenix.

What is the consensus analysts' recommendation for Zogenix?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zogenix in the last year. There are currently 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Zogenix.

What are Wall Street analysts saying about Zogenix stock?

Here are some recent quotes from research analysts about Zogenix stock:
  • 1. Northland Securities analysts commented, "We note that 1504 demonstrated 63% and 54% reductions in mean monthly convulsive seizure frequency, versus comparator arms that excluded or included stiripentol therapy, respectively. FINTEPLA was also shown to significantly extend seizure free intervals to ~1 month, with an exceptionally high response rate >70%." (7/8/2019)
  • 2. Mizuho analysts commented, "We gave consideration to (70% PoS). DCF: We assumed a 13% discount rate and a terminal value of 4.5x our estimated 2028 FCF of $861 mil. EV/Sales: we apply a 8x multiple to discounted 2025 sales of $352 mil. the U.S. market, we assume 4Q19 launch and peak market share of 75% (among new therapies) in 2028, equivalent to $526mn in peak sales; for EU and Japan, we assume late 2021 and late 2022 launches. For LGS, we project peak market penetration of 14% in 2028 in the U.S and PoS adjusted sales of $463mn." (3/19/2019)
  • 3. According to Zacks Investment Research, "Zogenix is a specialty biopharmaceutical company focused on developing therapies for patients with rare central nervous system conditions that have limited or no treatment options. The company is currently pursuing two therapies targeting the Dravet Syndrome and the Lennox-Gastaut Syndrome. " (2/23/2019)

Has Zogenix been receiving favorable news coverage?

News headlines about ZGNX stock have been trending negative this week, according to InfoTrie Sentiment Analysis. InfoTrie ranks the sentiment of news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Zogenix earned a media sentiment score of -2.7 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for Zogenix.

Are investors shorting Zogenix?

Zogenix saw a increase in short interest in June. As of June 30th, there was short interest totalling 9,644,400 shares, an increase of 6.8% from the May 30th total of 9,030,200 shares. Based on an average trading volume of 817,100 shares, the days-to-cover ratio is currently 11.8 days. Approximately 24.3% of the company's shares are short sold. View Zogenix's Current Options Chain.

Who are some of Zogenix's key competitors?

What other stocks do shareholders of Zogenix own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zogenix investors own include GW Pharmaceuticals PLC- (GWPH), Vanda Pharmaceuticals (VNDA), Alibaba Group (BABA), Canopy Growth (CGC), Gilead Sciences (GILD), QUALCOMM (QCOM), Southwest Airlines (LUV), Celgene (CELG), Novavax (NVAX) and AbbVie (ABBV).

Who are Zogenix's key executives?

Zogenix's management team includes the folowing people:
  • Dr. Stephen J. Farr, Co-Founder, CEO, Pres & Director (Age 60)
  • Mr. Michael P. Smith, Exec. VP, CFO, Treasurer & Sec. (Age 51)
  • Dr. Bradley S. Galer, Exec. VP & Chief Medical Officer (Age 57)
  • Dr. Gail M. Farfel, Exec. VP & Chief Devel. Officer (Age 55)
  • Mr. Ashish M. Sagrolikar, Exec. VP & Chief Commercial Officer

Who are Zogenix's major shareholders?

Zogenix's stock is owned by a number of of institutional and retail investors. Top institutional investors include Xact Kapitalforvaltning AB (0.02%). Company insiders that own Zogenix stock include Bradley S Galer, Cam L Garner, Erle T Mast, Gail M Farfel, Life Sciences Maste Perceptive, Michael P Smith, Renee P Tannenbaum, Roger Hawley and Stephen J Farr. View Institutional Ownership Trends for Zogenix.

Which institutional investors are selling Zogenix stock?

ZGNX stock was sold by a variety of institutional investors in the last quarter, including Xact Kapitalforvaltning AB. Company insiders that have sold Zogenix company stock in the last year include Cam L Garner, Erle T Mast, Gail M Farfel, Michael P Smith, Renee P Tannenbaum, Roger Hawley and Stephen J Farr. View Insider Buying and Selling for Zogenix.

How do I buy shares of Zogenix?

Shares of ZGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Zogenix's stock price today?

One share of ZGNX stock can currently be purchased for approximately $47.93.

How big of a company is Zogenix?

Zogenix has a market capitalization of $2.03 billion and generates $9.82 million in revenue each year. The company earns $-123,910,000.00 in net income (profit) each year or ($3.23) on an earnings per share basis. Zogenix employs 90 workers across the globe.View Additional Information About Zogenix.

What is Zogenix's official website?

The official website for Zogenix is http://www.zogenix.com/.

How can I contact Zogenix?

Zogenix's mailing address is 5959 Horton Street Suite 500, EMERYVILLE CA, 94608. The company can be reached via phone at 510-550-8300 or via email at [email protected]


MarketBeat Community Rating for Zogenix (NASDAQ ZGNX)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  387 (Thanks for Voting!)
Underperform Votes:  289 (Thanks for Voting!)
Total Votes:  676
MarketBeat's community ratings are surveys of what our community members think about Zogenix and other stocks. Vote "Outperform" if you believe ZGNX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZGNX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/18/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel